.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Shifting Paradigms in Ovarian Cancer

EP. 1: Risk-Reducing Surgery in Epithelial Ovarian Cancer

April 29th 2019

EP. 2: Ovarian Cancer: Neoadjuvant Chemo Vs Primary Debulking

April 29th 2019

EP. 3: Secondary Debulking Surgery in Ovarian Cancer

April 29th 2019

EP. 4: Current Role of VEGF-Targeted Therapy in Ovarian Cancer

April 29th 2019

EP. 5: SOLO-1 and PARP Inhibitors in Ovarian Cancer

April 29th 2019

EP. 6: Detecting Somatic BRCA1/2 Mutations in Ovarian Cancer

April 29th 2019

EP. 7: PARP + Maintenance Bevacizumab in Ovarian Cancer

April 29th 2019

EP. 8: Approaching Platinum-Sensitive Recurrent Ovarian Cancer

April 29th 2019

EP. 9: Ovarian Cancer: Selecting Between Available PARPs

April 29th 2019

EP. 10: Ovarian Cancer: Predictors of PARP Sensitivity

April 29th 2019

EP. 11: PARP Inhibitors in Ovarian Cancer: Safety Profile

April 29th 2019

EP. 12: Ovarian Cancer: Recurrence After PARP Inhibition

April 29th 2019

EP. 13: Rationale for Immunotherapy in Ovarian Cancer

April 29th 2019

EP. 14: I/O Combination Strategies in Ovarian Cancer

April 29th 2019

EP. 15: Ongoing Research in Ovarian Cancer

April 29th 2019

EP. 16: Outlook in Treating Patients With Ovarian Cancer

April 29th 2019